Cargando…

Axitinib in sequential therapy in metastatic renal cell carcinoma

Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchar, Agata, Hryciuk, Beata, Stec, Rafał, Mączewski, Michał, Szczylik, Cezary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371698/
https://www.ncbi.nlm.nih.gov/pubmed/28373826
http://dx.doi.org/10.5114/wo.2015.51823
_version_ 1782518473218326528
author Kuchar, Agata
Hryciuk, Beata
Stec, Rafał
Mączewski, Michał
Szczylik, Cezary
author_facet Kuchar, Agata
Hryciuk, Beata
Stec, Rafał
Mączewski, Michał
Szczylik, Cezary
author_sort Kuchar, Agata
collection PubMed
description Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived growth factor β (PDGRF-β) and c-KIT. This is a case report of a 57-year old female patient with a history of left nephrectomy due to clear cell renal cell carcinoma. The patient had received three prior systemic treatments (interferon – sorafenib – everolimus). After consecutive progression the patient was qualified to 4(th) line therapy – axitinib at a dose of 5 mg twice daily. Partial response to treatment was achieved. After 6 months therapy was stopped due to the disease progression. The total time to progression was 37.5 months. The total survival time from the disease diagnosis was 45 months. Based on literature date and own experience we showed that sequential treatment RCC is associated with improved survival. In summary, axitinib may be an effective drug after failure of tyrosine-kinase inhibitor (TKI) therapy in previous lines of therapy.
format Online
Article
Text
id pubmed-5371698
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-53716982017-04-03 Axitinib in sequential therapy in metastatic renal cell carcinoma Kuchar, Agata Hryciuk, Beata Stec, Rafał Mączewski, Michał Szczylik, Cezary Contemp Oncol (Pozn) Case Report Efficacy of new molecularly targeted drugs in the treatment of renal cell carcinoma (RCC), confirmed in clinical studies in relation to survival and prolongation of time to progression, has became a big chance for patients with metastatic renal cell cancer. Axitinib is a potent and selective receptor tyrosine kinase for vascular endothelial growth factor (VEGFR-1, -2, -3), platelet-derived growth factor β (PDGRF-β) and c-KIT. This is a case report of a 57-year old female patient with a history of left nephrectomy due to clear cell renal cell carcinoma. The patient had received three prior systemic treatments (interferon – sorafenib – everolimus). After consecutive progression the patient was qualified to 4(th) line therapy – axitinib at a dose of 5 mg twice daily. Partial response to treatment was achieved. After 6 months therapy was stopped due to the disease progression. The total time to progression was 37.5 months. The total survival time from the disease diagnosis was 45 months. Based on literature date and own experience we showed that sequential treatment RCC is associated with improved survival. In summary, axitinib may be an effective drug after failure of tyrosine-kinase inhibitor (TKI) therapy in previous lines of therapy. Termedia Publishing House 2016-12-20 2016 /pmc/articles/PMC5371698/ /pubmed/28373826 http://dx.doi.org/10.5114/wo.2015.51823 Text en Copyright: © 2016 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Case Report
Kuchar, Agata
Hryciuk, Beata
Stec, Rafał
Mączewski, Michał
Szczylik, Cezary
Axitinib in sequential therapy in metastatic renal cell carcinoma
title Axitinib in sequential therapy in metastatic renal cell carcinoma
title_full Axitinib in sequential therapy in metastatic renal cell carcinoma
title_fullStr Axitinib in sequential therapy in metastatic renal cell carcinoma
title_full_unstemmed Axitinib in sequential therapy in metastatic renal cell carcinoma
title_short Axitinib in sequential therapy in metastatic renal cell carcinoma
title_sort axitinib in sequential therapy in metastatic renal cell carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371698/
https://www.ncbi.nlm.nih.gov/pubmed/28373826
http://dx.doi.org/10.5114/wo.2015.51823
work_keys_str_mv AT kucharagata axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma
AT hryciukbeata axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma
AT stecrafał axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma
AT maczewskimichał axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma
AT szczylikcezary axitinibinsequentialtherapyinmetastaticrenalcellcarcinoma